AnaptysBio, Inc.
ANAB
$59.43
-$0.56-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -76.39% | 41.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -76.39% | 41.84% | |||
| Cost of Revenue | -82.19% | -18.62% | |||
| Gross Profit | -74.60% | 84.11% | |||
| SG&A Expenses | 65.95% | 54.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 45.58% | -0.64% | |||
| Operating Income | -151.77% | 92.78% | |||
| Income Before Tax | -206.34% | 228.82% | |||
| Income Tax Expenses | -50.62% | -- | |||
| Earnings from Continuing Operations | -206.59% | 228.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -206.59% | 228.29% | |||
| EBIT | -151.77% | 92.78% | |||
| EBITDA | -151.48% | 92.38% | |||
| EPS Basic | -203.24% | 228.80% | |||
| Normalized Basic EPS | -202.99% | 229.32% | |||
| EPS Diluted | -216.50% | 204.27% | |||
| Normalized Diluted EPS | -216.16% | 204.45% | |||
| Average Basic Shares Outstanding | -- | -- | |||
| Average Diluted Shares Outstanding | -1.13% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||